Cover Image
市場調查報告書

金黃色葡萄球菌感染:開發平台分析

Staphylococcus aureus Infections - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 200360
出版日期 內容資訊 英文 538 Pages
訂單完成後即時交付
價格
Back to Top
金黃色葡萄球菌感染:開發平台分析 Staphylococcus aureus Infections - Pipeline Review, H2 2015
出版日期: 2015年12月31日 內容資訊: 英文 538 Pages
簡介

黃色葡萄球菌為細菌的一種,這個感染疾病引起各種化膿性感染疾病和中毒症。症狀有蜂窩性組織炎、疼痛伴隨的發疹、噁心與嘔吐、發燒、肌肉痛、腹瀉、腹痛等。原因有免疫系統低下、燒燙傷、外科創傷。

本報告提供金黃色葡萄球菌感染的治療藥開發平台的現狀及最新更新的各開發階段比較分析、企業和研究機關正在開發的治療藥、治療藥的評估、後期階段及中止的計劃相關資訊等最新的新聞和發表。

簡介

金黃色葡萄球菌感染 概要

治療藥的開發

企業正在開發的治療藥

大學/機關研究中的治療藥

開發中產品概況

企業開發中的產品

大學/機關研究中的產品

開發治療藥的企業

治療藥的評估

藥物簡介

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7301IDB

Summary

Global Markets Direct's, 'Staphylococcus Aureus Infections - Pipeline Review, H2 2015', provides an overview of the Staphylococcus Aureus Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Staphylococcus Aureus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Staphylococcus Aureus Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Staphylococcus Aureus Infections
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Staphylococcus Aureus Infections and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Staphylococcus Aureus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Staphylococcus Aureus Infections pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Staphylococcus Aureus Infections
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Staphylococcus Aureus Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Staphylococcus aureus Infections Overview
  • Therapeutics Development
  • Staphylococcus aureus Infections - Therapeutics under Development by Companies
  • Staphylococcus aureus Infections - Therapeutics under Investigation by Universities/Institutes
  • Staphylococcus aureus Infections - Pipeline Products Glance
  • Staphylococcus aureus Infections - Products under Development by Companies
  • Staphylococcus aureus Infections - Products under Investigation by Universities/Institutes
  • Staphylococcus aureus Infections - Companies Involved in Therapeutics Development
  • Staphylococcus aureus Infections - Therapeutics Assessment
  • Drug Profiles
  • Staphylococcus aureus Infections - Recent Pipeline Updates
  • Staphylococcus aureus Infections - Dormant Projects
  • Staphylococcus aureus Infections - Discontinued Products
  • Staphylococcus aureus Infections - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Staphylococcus aureus Infections, H2 2015
  • Number of Products under Development for Staphylococcus aureus Infections - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Development by Companies, H2 2015 (Contd..1)
  • Number of Products under Development by Companies, H2 2015 (Contd..2)
  • Number of Products under Development by Companies, H2 2015 (Contd..3)
  • Number of Products under Development by Companies, H2 2015 (Contd..4)
  • Number of Products under Development by Companies, H2 2015 (Contd..5)
  • Number of Products under Development by Companies, H2 2015 (Contd..6)
  • Number of Products under Development by Companies, H2 2015 (Contd..7)
  • Number of Products under Development by Companies, H2 2015 (Contd..8)
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Development by Companies, H2 2015 (Contd..2)
  • Products under Development by Companies, H2 2015 (Contd..3)
  • Products under Development by Companies, H2 2015 (Contd..4)
  • Products under Development by Companies, H2 2015 (Contd..5)
  • Products under Development by Companies, H2 2015 (Contd..6)
  • Products under Development by Companies, H2 2015 (Contd..7)
  • Products under Development by Companies, H2 2015 (Contd..8)
  • Products under Development by Companies, H2 2015 (Contd..9)
  • Products under Development by Companies, H2 2015 (Contd..10)
  • Products under Development by Companies, H2 2015 (Contd..11)
  • Products under Development by Companies, H2 2015 (Contd..12)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..3)
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..4)
  • Staphylococcus aureus Infections - Pipeline by Absynth Biologics Limited, H2 2015
  • Staphylococcus aureus Infections - Pipeline by Actelion Ltd, H2 2015
  • Staphylococcus aureus Infections - Pipeline by Adenium Biotech ApS, H2 2015
  • Staphylococcus aureus Infections - Pipeline by AIMM Therapeutics B.V., H2 2015
  • Staphylococcus aureus Infections - Pipeline by Alchemia Limited, H2 2015
  • Staphylococcus aureus Infections - Pipeline by Allergan Plc, H2 2015
  • Staphylococcus aureus Infections - Pipeline by AlphaMab Co., Ltd, H2 2015
  • Staphylococcus aureus Infections - Pipeline by Alvogen Korea, H2 2015
  • Staphylococcus aureus Infections - Pipeline by AmpliPhi Biosciences Corporation, H2 2015
  • Staphylococcus aureus Infections - Pipeline by AnGes MG, Inc., H2 2015
  • Staphylococcus aureus Infections - Pipeline by Aphios Corporation, H2 2015
  • Staphylococcus aureus Infections - Pipeline by Arsanis Biosciences GmbH, H2 2015
  • Staphylococcus aureus Infections - Pipeline by AstraZeneca Plc, H2 2015
  • Staphylococcus aureus Infections - Pipeline by Aureogen Biosciences, Inc., H2 2015
  • Staphylococcus aureus Infections - Pipeline by Aurigene Discovery Technologies Limited, H2 2015
  • Staphylococcus aureus Infections - Pipeline by Bharat Biotech International Limited, H2 2015
  • Staphylococcus aureus Infections - Pipeline by BioDiem Ltd, H2 2015
  • Staphylococcus aureus Infections - Pipeline by Biomar Microbial Technologies, H2 2015
  • Staphylococcus aureus Infections - Pipeline by BioSource Pharm, Inc., H2 2015
  • Staphylococcus aureus Infections - Pipeline by C3 Jian, Inc, H2 2015
  • Staphylococcus aureus Infections - Pipeline by Cellceutix Corporation, H2 2015
  • Staphylococcus aureus Infections - Pipeline by Cempra, Inc., H2 2015
  • Staphylococcus aureus Infections - Pipeline by ContraFect Corporation, H2 2015
  • Staphylococcus aureus Infections - Pipeline by CrystalGenomics, Inc., H2 2015
  • Staphylococcus aureus Infections - Pipeline by CSA Biotechnologies LLC , H2 2015
  • Staphylococcus aureus Infections - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
  • Staphylococcus aureus Infections - Pipeline by Debiopharm International S.A., H2 2015
  • Staphylococcus aureus Infections - Pipeline by DesignMedix, Inc., H2 2015
  • Staphylococcus aureus Infections - Pipeline by Destiny Pharma Limited, H2 2015
  • Staphylococcus aureus Infections - Pipeline by Dong-A Socio Group, H2 2015
  • Staphylococcus aureus Infections - Pipeline by Ensol Biosciences Inc., H2 2015
  • Staphylococcus aureus Infections - Pipeline by Evaxion Biotech, H2 2015
  • Staphylococcus aureus Infections - Pipeline by Excelimmune, Inc., H2 2015
  • Staphylococcus aureus Infections - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
  • Staphylococcus aureus Infections - Pipeline by Galapagos NV, H2 2015
  • Staphylococcus aureus Infections - Pipeline by GangaGen Inc., H2 2015
  • Staphylococcus aureus Infections - Pipeline by GlaxoSmithKline Plc, H2 2015
  • Staphylococcus aureus Infections - Pipeline by Helix BioMedix, Inc., H2 2015
  • Staphylococcus aureus Infections - Pipeline by Hsiri Therapeutics, LLC, H2 2015
  • Staphylococcus aureus Infections - Pipeline by Humabs BioMed SA, H2 2015
  • Staphylococcus aureus Infections - Pipeline by Ildong Pharmaceutical Co., Ltd., H2 2015
  • Staphylococcus aureus Infections - Pipeline by Imaxio SA, H2 2015
  • Staphylococcus aureus Infections - Pipeline by Immupharma Plc, H2 2015
  • Staphylococcus aureus Infections - Pipeline by ImmuVen, Inc., H2 2015
  • Staphylococcus aureus Infections - Pipeline by Integrated BioTherapeutics, Inc., H2 2015
  • Staphylococcus aureus Infections - Pipeline by iNtRON Biotechnology Inc., H2 2015
  • Staphylococcus aureus Infections - Pipeline by ioGenetics, Inc., H2 2015
  • Staphylococcus aureus Infections - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2015
  • Staphylococcus aureus Infections - Pipeline by Lascco SA, H2 2015
  • Staphylococcus aureus Infections - Pipeline by LegoChem Biosciences, Inc, H2 2015
  • Staphylococcus aureus Infections - Pipeline by Lytix Biopharma AS, H2 2015
  • Staphylococcus aureus Infections - Pipeline by Madam Therapeutics B.V., H2 2015
  • Staphylococcus aureus Infections - Pipeline by MedImmune, LLC, H2 2015
  • Staphylococcus aureus Infections - Pipeline by Melinta Therapeutics, Inc, H2 2015
  • Staphylococcus aureus Infections - Pipeline by Merck & Co., Inc., H2 2015
  • Staphylococcus aureus Infections - Pipeline by MGB Biopharma Limited, H2 2015
  • Staphylococcus aureus Infections - Pipeline by Microbiotix, Inc., H2 2015
  • Staphylococcus aureus Infections - Pipeline by MicuRx Pharmaceuticals, Inc., H2 2015
  • Staphylococcus aureus Infections - Pipeline by MorphoSys AG, H2 2015
  • Staphylococcus aureus Infections - Pipeline by Morphotek, Inc., H2 2015
  • Staphylococcus aureus Infections - Pipeline by Motif BioSciences, Inc., H2 2015
  • Staphylococcus aureus Infections - Pipeline by Nabriva Therapeutics AG, H2 2015
  • Staphylococcus aureus Infections - Pipeline by NanoBio Corporation, H2 2015
  • Staphylococcus aureus Infections - Pipeline by NovaBay Pharmaceuticals, Inc., H2 2015
  • Staphylococcus aureus Infections - Pipeline by Novabiotics Limited, H2 2015
  • Staphylococcus aureus Infections - Pipeline by NovaDigm Therapeutics, Inc., H2 2015
  • Staphylococcus aureus Infections - Pipeline by Novan, Inc., H2 2015
  • Staphylococcus aureus Infections - Pipeline by NovoBiotic Pharmaceuticals, LLC, H2 2015
  • Staphylococcus aureus Infections - Pipeline by Omnia Molecular Ltd., H2 2015
  • Staphylococcus aureus Infections - Pipeline by Oragenics, Inc., H2 2015
  • Staphylococcus aureus Infections - Pipeline by Pepscan Presto BV, H2 2015
  • Staphylococcus aureus Infections - Pipeline by Pfizer Inc., H2 2015
  • Staphylococcus aureus Infections - Pipeline by PharmaIN Corporation, H2 2015
  • Staphylococcus aureus Infections - Pipeline by Phico Therapeutics Limited, H2 2015
  • Staphylococcus aureus Infections - Pipeline by Phylogica Limited, H2 2015
  • Staphylococcus aureus Infections - Pipeline by Pono Pharma, H2 2015
  • Staphylococcus aureus Infections - Pipeline by Procarta Biosystems Ltd, H2 2015
  • Staphylococcus aureus Infections - Pipeline by QureTech Bio AB, H2 2015
  • Staphylococcus aureus Infections - Pipeline by Redx Pharma Plc, H2 2015
  • Staphylococcus aureus Infections - Pipeline by Sarepta Therapeutics, Inc., H2 2015
  • Staphylococcus aureus Infections - Pipeline by Savara Inc., H2 2015
  • Staphylococcus aureus Infections - Pipeline by Sealife PHARMA GMBH, H2 2015
  • Staphylococcus aureus Infections - Pipeline by Sentinella Pharmaceuticals, Inc., H2 2015
  • Staphylococcus aureus Infections - Pipeline by Soligenix, Inc., H2 2015
  • Staphylococcus aureus Infections - Pipeline by Sorrento Therapeutics, Inc., H2 2015
  • Staphylococcus aureus Infections - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015
  • Staphylococcus aureus Infections - Pipeline by Syntiron LLC, H2 2015
  • Staphylococcus aureus Infections - Pipeline by Taejoon Pharm Co., Ltd., H2 2015
  • Staphylococcus aureus Infections - Pipeline by TAXIS Pharmaceuticals, Inc., H2 2015
  • Staphylococcus aureus Infections - Pipeline by Techulon, Inc., H2 2015
  • Staphylococcus aureus Infections - Pipeline by Telephus Medical LLC, H2 2015
  • Staphylococcus aureus Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2015
  • Staphylococcus aureus Infections - Pipeline by TGV-Laboratories, H2 2015
  • Staphylococcus aureus Infections - Pipeline by Theravance Biopharma, Inc., H2 2015
  • Staphylococcus aureus Infections - Pipeline by United Therapeutics Corporation, H2 2015
  • Staphylococcus aureus Infections - Pipeline by Valevia UK Limited, H2 2015
  • Staphylococcus aureus Infections - Pipeline by Varinel, Inc., H2 2015
  • Staphylococcus aureus Infections - Pipeline by Wintermute Biomedical LLC, H2 2015
  • Staphylococcus aureus Infections - Pipeline by Wockhardt Limited, H2 2015
  • Staphylococcus aureus Infections - Pipeline by XBiotech USA, Inc., H2 2015
  • Staphylococcus aureus Infections - Pipeline by Yungjin Pharm. Co., Ltd., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Staphylococcus aureus Infections Therapeutics - Recent Pipeline Updates, H2 2015
  • Staphylococcus aureus Infections - Dormant Projects, H2 2015
  • Staphylococcus aureus Infections - Dormant Projects (Contd..1), H2 2015
  • Staphylococcus aureus Infections - Dormant Projects (Contd..2), H2 2015
  • Staphylococcus aureus Infections - Dormant Projects (Contd..3), H2 2015
  • Staphylococcus aureus Infections - Dormant Projects (Contd..4), H2 2015
  • Staphylococcus aureus Infections - Dormant Projects (Contd..5), H2 2015
  • Staphylococcus aureus Infections - Dormant Projects (Contd..6), H2 2015
  • Staphylococcus aureus Infections - Dormant Projects (Contd..7), H2 2015
  • Staphylococcus aureus Infections - Dormant Projects (Contd..8), H2 2015
  • Staphylococcus aureus Infections - Dormant Projects (Contd..9), H2 2015
  • Staphylococcus aureus Infections - Dormant Projects (Contd..10), H2 2015
  • Staphylococcus aureus Infections - Dormant Projects (Contd..11), H2 2015
  • Staphylococcus aureus Infections - Dormant Projects (Contd..12), H2 2015
  • Staphylococcus aureus Infections - Discontinued Products, H2 2015
  • Staphylococcus aureus Infections - Discontinued Products (Contd..1), H2 2015

List of Figures

  • Number of Products under Development for Staphylococcus aureus Infections, H2 2015
  • Number of Products under Development for Staphylococcus aureus Infections - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top